NASDAQ$DSGN

Design Therapeutics Inc · Q1 2020 earnings

Q1 2020 earnings · · Investor relations

Headline financials

Total Revenue

$142K

No prior period
EPS (adj)

-$0.02

No prior period
Net Income

-$663K

No prior period
Operating Income

-$623K

No prior period
Gross Profit

-$235K

No prior period
R&D Expense

$377K

No prior period

Revenue & EPS history

Design Therapeutics · Revenue · Quarterly

$142K

Q1 2020

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports

Historical avg

-2.2%

Avg return

Earnings day

+1.7%

Avg return

5 days after

+3.2%

Avg return

30 days after

50%

10 / 20 earnings

Positive

+15.1%

Q4 2023

Best reaction

-71.7%

Q2 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.0%+3.8%-16.2%
Q4 2025+3.2%+0.7%+26.1%
Q3 2025+10.7%+10.8%+42.2%
Q2 2025-8.9%+14.5%+48.3%
Q1 2025+0.3%+10.3%+10.3%
Q4 2024+0.4%+2.5%-27.2%
Q3 2024-1.9%+16.3%+7.9%
Q1 2024+1.7%-3.0%-17.9%
Q4 2023+15.1%+50.8%+48.4%
Q3 2023+13.9%+10.4%+27.4%
Q2 2023-71.7%-72.8%-65.2%
Q1 2023-12.2%-12.6%-26.4%
Q4 2022-0.6%-8.1%-24.8%
Q3 2022-0.3%-0.8%-9.7%
Q2 2022+0.3%+13.5%+5.5%
Q1 2022-1.5%-2.4%+30.9%
Q4 2021-1.8%-0.8%-10.0%
Q3 2021+4.8%+10.7%-3.8%
Q2 2021+9.9%+7.9%+19.7%
Q1 2021-6.0%-18.0%-1.8%
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro